Home
/

Eosinophils: your immune system's allergy and parasite specialists

REVIEWED BY
Bill Maish, MD
Clinical Content Consultant
Published
May 30, 2026
Last updated
May 30, 2026
Key takeaway:

Eosinophils are immune cells with a typical reference band of 50–500 cells/µL; persistent counts at or above 1,500 cells/µL are labeled hypereosinophilia and warrant investigation, since prolonged tissue exposure to eosinophil proteins can injure the heart, lungs, and nerves. The absolute count (AEC) is more reliable than the percentage, which shifts whenever other white cell populations rise or fall.

Read more →
Table of contents

What eosinophils actually are, in plain terms

Eosinophils are a type of white blood cell measured on a complete blood count (CBC) with differential. Labs report them as a percentage of white cells and, more usefully, as an absolute eosinophil count (AEC) — the number of eosinophils per microliter of blood. Made in the bone marrow, they circulate briefly before migrating into tissues like the lungs and gut. Rising values usually signal a Type 2 immune response linked to allergies, asthma, certain infections (especially helminths), or drug reactions; falling values often reflect cortisol effects from stress or corticosteroid medicines.

How eosinophils signal allergy, parasites, and inflammation

Eosinophils function as the immune system's allergy-and-parasite specialists. T helper 2 (Th2) cells call them in with IL-5; local chemokines like eotaxin guide them to tissues; once there, eosinophils degranulate — releasing major basic protein and eosinophil peroxidase, proteins that can punch holes in parasites but also irritate airway lining or esophageal tissue when allergens are the target.

Importantly, eosinophils do not measure total allergic burden. They reflect the immune system's current Type 2 activation state, which includes parasite and drug-hypersensitivity signals beyond allergy alone.

Counts shift with environment and hormones. During allergy season, more signal means more eosinophils. After a dose of prednisone, fewer — because corticosteroids quiet IL-5 and keep eosinophils in the bone marrow. There is a daily rhythm too: eosinophils tend to be higher at night and lower in the morning, tracking the cortisol curve — a confounder that matters when comparing results drawn at different times of day.

Acute bacterial infections push neutrophils up, which can make the eosinophil percentage look smaller even if the absolute count barely moves. That is why the AEC is the more stable metric, and why single snapshots are less meaningful than trends paired with symptoms and context.

Reading your absolute eosinophil count, by band

Reference intervals are built from large groups of generally healthy people. Many labs flag an absolute count above roughly 500 cells/µL, with typical reference bands around 50–500 cells/µL (0.05–0.5 ×10⁹/L), though ranges are lab-specific. Children often run higher; values drift across seasons; time of day changes the signal. On a differential, 1–4% is generally considered normal, but the AEC is the more stable metric because the percentage can shift simply when other white cells rise or fall.

In asthma research and guidelines, cut points like 150 or 300 cells/µL are used to identify a Type 2–high pattern that predicts response to certain anti-IL-5 therapies. In hematology, persistent counts at or above 1,500 cells/µL are labeled hypereosinophilia and prompt a search for causes and organ involvement. Results should always be interpreted with the full story — age, symptoms, medications, travel, and timing — not in isolation.

Normal eosinophils

An AEC of roughly 100–500 cells/µL (some labs use 50–500 cells/µL) falls within the typical reference range. On a differential, 1–4% is generally normal, but because the percentage shifts whenever other white cell populations rise or fall, the AEC is the more reliable figure. Note that morning draws tend to show lower eosinophil percentages due to the AM cortisol peak — lab-to-lab variation and time-of-day of the draw should both be considered before reading too much into a single result.

High eosinophils

Counts in the 500–1,500 cells/µL range represent mild eosinophilia. Most commonly this reflects allergic disease — asthma, hay fever, eczema — where the immune system is producing IgE against harmless triggers. It can show up as a mild bump during spring blooms or a sustained elevation if airway inflammation is active. In some people the blood count looks normal while the tissue tells the story, which is why sputum or tissue biopsies are sometimes used in specialty care.

Parasitic infections, especially helminths, are another major driver worldwide. Travel to or residence in endemic regions, eating undercooked freshwater fish or pork, or walking barefoot where soil-transmitted parasites are common can all set the stage, with counts sometimes climbing moderately to markedly over a timeline of weeks.

Drugs can also raise eosinophils. Delayed hypersensitivity reactions — fever, rash, and eosinophilia — are classic, with patterns like DRESS (drug reaction with eosinophilia and systemic symptoms) requiring prompt medical evaluation. Less common but important causes include eosinophilic esophagitis or gastroenteritis, eosinophilic granulomatosis with polyangiitis (EGPA), certain lymphomas, and primary bone marrow disorders. In these scenarios, eosinophils are a clue, not the diagnosis.

Persistent eosinophils at or above 1,500 cells/µL over repeat tests warrant attention: ongoing tissue exposure to eosinophil granule proteins can injure organs including the heart, lungs, skin, and nerves.

Low eosinophils

Low eosinophils are usually physiologic. Corticosteroids — inhaled or systemic — push counts down by dialing back IL-5 and keeping eosinophils from leaving the marrow. The body's own cortisol does the same under acute stress, after high-intensity exercise, or in Cushing syndrome. During acute bacterial infections, eosinophils can dip while neutrophils surge, a pattern sometimes called eosinopenia. In pregnancy, especially later trimesters, eosinophils often run a bit lower due to hormonal shifts.

A low count is not inherently favorable — it is a signal of current immune tone or medication effect. If a sudden drop appears, the context matters: new steroids, time of day, an active illness, or a hard workout. The eosinophil percentage can also look low simply because other white cells are elevated.

Factors that move your eosinophil count

Several confirmed confounders shift eosinophil counts independently of any underlying condition:

  • Corticosteroids (inhaled or systemic) lower eosinophils by dialing back IL-5 signaling and keeping eosinophils in the bone marrow.
  • Biologics targeting IL-5 (such as mepolizumab or benralizumab) can markedly reduce counts; leukotriene modifiers and allergen immunotherapy tune the pathway at other steps.
  • Time of day / diurnal rhythm — eosinophils are higher at night and lower in the morning, tracking the cortisol curve. Morning draws tend to show lower values.
  • Acute bacterial infection — a neutrophil surge makes the eosinophil percentage look smaller even when the absolute count is unchanged.
  • Intense exercise — a transient cortisol spike can briefly suppress counts; regular moderate training is associated with improved airway function and symptom control in asthma, and structured exercise programs have been shown to reduce exhaled nitric oxide (a marker of airway inflammation) in some participants.
  • Pregnancy — eosinophils often run lower, particularly in later trimesters, due to hormonal shifts.
  • Adrenal insufficiency — reduced cortisol output can raise eosinophil counts.
  • Drug hypersensitivity — certain antibiotics, anti-seizure medicines, and other drugs can trigger eosinophilia through hypersensitivity mechanisms.
  • Allergy season — increased allergen exposure drives greater Type 2 activation and higher counts.
  • Parasite exposure and travel history — helminth infections are a major driver of elevated counts; travel to endemic regions is a key contextual factor.
  • Vitamin D status — vitamin D has been associated with asthma control in some research, suggesting a possible modulatory role in Type 2 pathways, though results are mixed.
  • Eosinophilic esophagitis — in this condition, trigger avoidance can reduce eosinophilic inflammation; this is a strategy best guided by a clinician.

The panel that reads eosinophils in context

Eosinophils rarely tell the whole story by themselves. These tests add the most interpretive value:

  • White blood cells (WBC) with differential — the full differential contextualizes whether isolated eosinophilia or a broader immune shift is occurring. High neutrophils with a low eosinophil percentage suggests an acute bacterial tilt, not an allergic pattern.
  • High-sensitivity CRP (hs-CRP) — CRP can stay relatively low in eosinophil-driven conditions (allergic, parasitic), helping distinguish them from classic bacterial inflammation where CRP surges.
  • Cortisol — explains diurnal eosinophil swings; morning cortisol peaks suppress eosinophils, so the time of day of the blood draw matters when interpreting a percentage result.
  • Basophils — basophils are elevated alongside eosinophils in many allergic conditions; discordance (high eosinophils with normal basophils) may point toward parasitic rather than pure atopic drivers.

In the right context, stool ova and parasite testing or targeted serology clarifies suspected helminth infections. Total IgE and exhaled nitric oxide (FeNO) are used in specialty care to further characterize Type 2–high patterns. When these pieces are viewed together, patterns emerge that guide smarter testing and fewer diagnostic blind alleys.

When to recheck an abnormal eosinophil count

Eosinophil counts have two response speeds. Acute shifts happen in days — starting corticosteroids, for example, can suppress counts within 24–48 hours. But the baseline allergic or inflammatory state that drives elevated counts changes over months. Quarterly retesting often captures seasonal variation or medication effects rather than a true baseline change.

For trend assessment — allergy management, parasitic infection treatment, or biologic therapy — retesting every 6–12 months under consistent conditions gives a more meaningful signal. For acute workup of significant eosinophilia above 1,500 cells/µL, the follow-up cadence is determined by clinical severity and is typically set by the rheumatology or allergy team managing the case.

Practical consistency rules apply regardless of the reason for retesting:

  • Use the same laboratory where possible, to minimize inter-lab reference range variation.
  • Draw blood at the same time of day — morning is preferred to minimize diurnal-rhythm noise.
  • Confirm the result is being reported as an absolute eosinophil count (AEC) rather than percentage only; percentage-only reporting can be misleading when other white cell populations shift.

When eosinophilia warrants a closer medical look

A baseline AEC gives you a reference point. Seasonal checks show whether spring pollen is a blip or a sustained surge. Post-travel testing can catch helminth exposures before they become long, complicated stories. Medication changes — starting an inhaled steroid, adjusting a biologic — are easier to evaluate when you can see their fingerprint on your count over time.

Persistent eosinophilia at or above 1,500 cells/µL over repeat tests is the clearest prompt for a closer look. Ongoing tissue exposure to eosinophil granule proteins can injure the heart, lungs, skin, and nerves, which is why early detection and monitoring matter in hypereosinophilic syndromes. In asthma, eosinophil-driven airway inflammation correlates with exacerbations and can contribute to airway remodeling if undertreated — guidelines emphasize control and monitoring for this reason. At the other end, persistently suppressed eosinophils often reflect sustained corticosteroid exposure, which cues a conversation about symptom control, side effects, and whether other strategies might reduce steroid load.

The goal is not to chase a perfect eosinophil number. It is to watch the pattern: counts rising each spring, falling with consistent asthma control, spiking after travel. Those arcs, linked with symptoms and context, are where prevention and early course-correction live. Tracking eosinophils alongside a comprehensive biomarker panel — immune activity, airway inflammation signals, hormonal rhythms, metabolic context — gives the kind of panorama that moves beyond averages. That means fewer surprises, more informed choices, and a tighter feedback loop between what changes in your life and what changes in your labs. Learn more about Superpower and our approach to proactive health.

FAQs

Eosinophils are a type of white blood cell that plays a central role in immune defense against parasitic infections and in the regulation of allergic and inflammatory responses. They are produced in the bone marrow and circulate in the blood, but most eosinophils reside in tissues, particularly in the gastrointestinal tract. When the body detects allergens, parasites, or certain inflammatory triggers, eosinophil production and tissue recruitment increase.
Normal absolute eosinophil count typically ranges from 100 to 500 cells per microliter (0.1 to 0.5 x 10^9/L). On a CBC differential, eosinophils normally make up 1 to 4% of total white blood cells. Mild eosinophilia is defined as 500 to 1,500 cells/uL; moderate as 1,500 to 5,000; and severe (or hypereosinophilia) as above 5,000 cells/uL. The absolute count is more clinically informative than the percentage alone.
The most common causes worldwide are allergic conditions (asthma, hay fever, eczema, food allergy) and parasitic infections, particularly tissue-invasive helminths. In industrialized countries, allergic disease is the predominant driver. Other causes include drug hypersensitivity reactions, autoimmune conditions, inflammatory bowel disease, and, in significant elevations, rare conditions like eosinophilic granulomatosis with polyangiitis (EGPA) or hypereosinophilic syndrome. Adrenal insufficiency also raises eosinophil count.
Low eosinophil count (eosinopenia), generally below 100 cells/uL, is less commonly discussed. It can occur acutely during the stress response, in sepsis, with high-dose corticosteroid use, or as an early sign of Cushing's syndrome due to elevated endogenous cortisol. Eosinopenia is occasionally used as a marker of acute stress response severity in critical illness. Isolated low eosinophils in an otherwise normal CBC are rarely clinically significant.
Mild eosinophilia often causes no symptoms and is found incidentally on routine bloodwork. When it reflects an underlying allergic condition, symptoms relate to that condition: nasal congestion, itching, wheezing, or skin rash. In more significant eosinophilia, particularly when eosinophils infiltrate organ tissue, symptoms can include abdominal pain, cough, shortness of breath, or, in severe cases, cardiac or neurological manifestations from end-organ damage.
Mildly elevated eosinophils (500 to 1,000 cells/uL) are common and usually reflect an identifiable, manageable cause such as seasonal allergies, a reaction to a medication, or a resolved parasitic exposure. A single mildly elevated result is rarely urgent. Persistent elevation, a count that is rising over serial tests, or elevation above 1,500 cells/uL warrants a more thorough workup to identify the underlying cause, particularly if accompanied by symptoms.

References

  1. Wechsler, M. E., Munitz, A., Ackerman, S. J., Drake, M. G., Jackson, D. J., Wardlaw, A. J., Dougan, S. K., Berdnikovs, S., Schleich, F., Matucci, A., Chanez, P., Prazma, C. M., Howarth, P., Weller, P. F., & Merkel, P. A. (2021). Eosinophils in Health and Disease: A State-of-the-Art Review. Mayo Clinic proceedings, 96(10), 2694-2707. https://doi.org/10.1016/j.mayocp.2021.04.025
  2. Holguin, F., Cardet, J. C., Chung, K. F., Diver, S., Ferreira, D. S., Fitzpatrick, A., Gaga, M., Kellermeyer, L., Khurana, S., Knight, S., McDonald, V. M., Morgan, R. L., Ortega, V. E., Rigau, D., Subbarao, P., Tonia, T., Adcock, I. M., Bleecker, E. R., Brightling, C., ... Bush, A. (2020). Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. The European respiratory journal, 55(1). https://doi.org/10.1183/13993003.00588-2019
  3. Busse, W., Chupp, G., Nagase, H., Albers, F. C., Doyle, S., Shen, Q., Bratton, D. J., & Gunsoy, N. B. (2019). Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison. The Journal of allergy and clinical immunology, 143(1), 190-200.e20. https://doi.org/10.1016/j.jaci.2018.08.031
  4. Requena, G., van den Bosch, J., Akuthota, P., Kovalszki, A., Steinfeld, J., Kwon, N., & Van Dyke, M. K. (2022). Clinical Profile and Treatment in Hypereosinophilic Syndrome Variants: A Pragmatic Review. The journal of allergy and clinical immunology. In practice, 10(8), 2125-2134. https://doi.org/10.1016/j.jaip.2022.03.034
  5. Cacoub, P., Musette, P., Descamps, V., Meyer, O., Speirs, C., Finzi, L., & Roujeau, J. C. (2011). The DRESS syndrome: a literature review. The American journal of medicine, 124(7), 588-97. https://doi.org/10.1016/j.amjmed.2011.01.017
  6. Thakker, C., Warrell, C., Barrett, J., Booth, H. L., Chiodini, P. L., Defres, S., Falconer, J., Jacobs, N., Jones, J., Lambert, J., Leong, C., McBride, A., Moore, E., Moshiri, T., Nabarro, L. E., O'Hara, G., Stone, N., van Halsema, C., Checkley, A. M., & British Infection Association (2025). UK guidelines for the investigation and management of eosinophilia in returning travellers and migrants. The Journal of infection, 90(2), 106328. https://doi.org/10.1016/j.jinf.2024.106328

Built by the world’s top doctors and scientists

Dr Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

Learn more

Dr Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

Learn more

Dr Robert Lufkin

UCLA Medical Professor, NYT Bestselling Author

A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

Learn more

Dr Abe Malkin

Founder & Medical Director of Concierge MD

Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

Learn more
Membership slide 1
Membership slide 1
Membership slide 2
Membership slide 3
1 / 3

Your membership starts here

Annual 100+ biomarker panel

Data dashboard and digital twin

Upload past labs and connect wearables

Personalized health protocol

24/7 care team access

AI companion for all health questions

Marketplace with additional solutions

$199

/year*

Billed annually

HSA/ FSA eligible
Cancel anytime
Results in a week

* Pricing may vary for members in New York and New Jersey